UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14D-9

 

 

Solicitation/Recommendation Statement under Section 14(d)(4)

of the Securities Exchange Act of 1934

(Amendment No. 16)

 

 

HUMAN GENOME SCIENCES, INC.

(Name of Subject Company)

HUMAN GENOME SCIENCES, INC.

(Name of Person Filing Statement)

 

 

Common Stock, $0.01 par value per share

(Title of Class of Securities)

444903108

(CUSIP Number of Class of Securities)

James H. Davis

Executive Vice President, General Counsel and Secretary

14200 Shady Grove Road

Rockville, Maryland 20850-7464

(301) 309-8504

(Name, address and telephone number of person authorized to receive notices

and communications on behalf of the person filing statement)

 

 

With copies to:

Michael P. Rogan

Marc S. Gerber

Skadden, Arps, Slate, Meagher & Flom LLP

1440 New York Avenue, NW

Washington, D.C. 20005

(202) 371-7000

 

Robert W. Smith, Jr.

Jason C. Harmon

DLA Piper LLP (US)

6225 Smith Avenue

Baltimore, Maryland 21209
(410) 580-3000

 

 

 

¨  

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

 


Introduction

This Amendment No. 16 to the Schedule 14D-9 (the “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended from time to time, the “Statement”) originally filed by Human Genome Sciences, Inc., a Delaware corporation (“HGS” or the “Company”), with the Securities and Exchange Commission (the “SEC”) on May 17, 2012. Except as otherwise set forth in this Amendment, the information set forth in the Statement remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment. Capitalized terms used but not defined herein have the meanings ascribed to them in the Statement.

Item 8. Additional Information

Item 8 of the Statement is hereby amended and supplemented by adding the following text as new paragraphs immediately following the last paragraph under the heading “Litigation”:

With respect to the foregoing case, David, et al. v. Human Genome Sciences, Inc., et al. , C.A. No. 1:12-cv-00965, on July 26, 2012, the District Court denied plaintiffs’ motion for a temporary restraining order.

With respect to the foregoing case, Markovic v. Human Genome Sciences, Inc., et al. , Docket No. 366054-V, on July 26, 2012, the Circuit Court heard oral arguments and denied plaintiff’s motion for a temporary restraining order.

 

1


SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

HUMAN GENOME SCIENCES, INC.
By:  

/s/ James H. Davis

Name:   James H. Davis
Title:   Executive Vice President, General Counsel and Secretary

Dated: July 26, 2012

Grafico Azioni Human Genome Sciences (NASDAQ:HGSI)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Human Genome Sciences
Grafico Azioni Human Genome Sciences (NASDAQ:HGSI)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Human Genome Sciences